Essais liés11clinical trials
VilleCity of Saint Peterslocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT07517263

Ouvrir le site du centre

Essais cliniques associés

11
MoléculeIndication / populationPhaseNCTTitreStatut
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL Maladie coronarienne Phase 3 NCT05739383 A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. ACTIVE_NOT_RECRUITING
Retatrutide Maladie rénale chronique Phase 3 NCT06383390 The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) ACTIVE_NOT_RECRUITING
Pelacarsen (TQJ230) Accident vasculaire cérébral Phase 3 NCT07517263 An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) ACTIVE_NOT_RECRUITING
Atogepant Migraine Phase 3 NCT03777059 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine COMPLETED
Atogepant Migraine Phase 3 NCT03939312 Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine COMPLETED
Dihydroergotamine Migraine Phase 3 NCT03901482 EMERGE — A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine COMPLETED
Erenumab Migraine Phase 4 NCT04252742 EMBRACE — Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine COMPLETED
ASY202 Migraine Phase 2 NCT07646613 Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients RECRUITING
Rimegepant Migraine Phase 3 NCT07729462 A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine RECRUITING
Elismetrep Migraine Phase 3 NCT07645924 A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine RECRUITING
Elismetrep Migraine Phase 3 NCT07674654 A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine RECRUITING